Effectiveness of Inactivated and mRNA COVID-19 Vaccines Against SARS-CoV-2 Infection, Severe Disease and Mortality in the Geriatric Population

Basit Öğe Kaydı
dc.authoridOzudogru, Osman/0000-0003-1212-2251
dc.authoridAcer, Omer/0000-0002-5314-0475
dc.contributor.authorGenc Bahce, Yasemin
dc.contributor.authorAcer, Omer
dc.contributor.authorOzudogru, Osman
dc.date.accessioned2024-12-24T19:24:24Z
dc.date.available2024-12-24T19:24:24Z
dc.date.issued2023
dc.departmentSiirt Üniversitesi
dc.description.abstractOlder age (>60 years) has been identified as the main risk factor for COVID-19. In this study, we aimed to evaluate the efficacy of Pfizer-BioNTech and CoronaVac vaccines against COVID-19 infection, serious illness, and mortality in the geriatric population. We found that 2 doses of CoronaVac vaccine were ineffective in protecting against COVID-19 infection in people over 65 years of age, while the vaccine efficacy (VE) of the mRNA vaccine against COVID-19 was 80% (95% CI 70-87). The VE of full vaccination with BioNTech was 89% (95% CI 53-97) against hospitalization, 79% (95% CI 0-97) against death, and 79% (95% CI 0-97) against intensive care unit (ICU) admission. However, the VE of full vaccination with CoronaVac was 50% (95% CI 33-63) against hospitalization, 53% (95% CI 26-70) against ICU admission, and 56% (95% CI 30-73) against death. In conclusion, we found that the mRNA vaccine has higher efficacy against severe COVID-19 infection and mortality in the geriatric population than the inactivated vaccine. Booster doses of vaccines should be considered in increasing the effectiveness of inactivated vaccines. Given the potential of SARS-CoV-2 mutations evading vaccination protection and the risk of reduced immunity over time, regular monitoring of vaccine effectiveness in the real world is critical.
dc.identifier.doi10.1007/s00284-023-03322-z
dc.identifier.issn0343-8651
dc.identifier.issn1432-0991
dc.identifier.issue6
dc.identifier.pmid37160453
dc.identifier.scopus2-s2.0-85158939510
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.1007/s00284-023-03322-z
dc.identifier.urihttps://hdl.handle.net/20.500.12604/5974
dc.identifier.volume80
dc.identifier.wosWOS:000984914200001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofCurrent Microbiology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241222
dc.titleEffectiveness of Inactivated and mRNA COVID-19 Vaccines Against SARS-CoV-2 Infection, Severe Disease and Mortality in the Geriatric Population
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu